University College London Hospitals NHS Foundation Trust, University College London, London, UK.
MRC Centre for Reproductive Health, Queens Medical Research Institute, Edinburgh, UK.
Lancet Haematol. 2021 Feb;8(2):e149-e160. doi: 10.1016/S2352-3026(20)30324-0.
As survival rates in teenagers and young adults diagnosed with haematological malignancies now exceed 70%, it is important that long-term quality of life, including measures to protect future fertility, are considered and discussed with patients and their families. Although discussion on the effect of planned cancer treatment on fertility is standard of care, knowledge of potential fertility treatment options and when they should be offered in haematological malignancies is not always so clear. In each case, the advice on the appropriate preservation of fertility depends upon a complex interplay of factors, weighing out the risk of future infertility against the risk of fertility preservation treatment, and recommendations must be made on a case-by-case basis. The aim of this Review is to evaluate the gonadotoxicity of treatments of prevalent haematological malignancies in teenagers and young adults, and provide an evidence-based framework to help with fertility discussion and management at the time of diagnosis, relapse or resistant disease, and in long-term follow-up settings.
由于现在诊断出患有血液系统恶性肿瘤的青少年和年轻人的存活率超过 70%,因此重要的是要考虑并与患者及其家属讨论长期的生活质量,包括保护未来生育能力的措施。虽然关于计划中的癌症治疗对生育能力影响的讨论是护理标准,但对于血液系统恶性肿瘤中潜在生育治疗选择及其应何时提供的知识并不总是那么明确。在每种情况下,关于适当保留生育能力的建议都取决于复杂的因素相互作用,权衡未来不孕的风险与生育保护治疗的风险,并且必须根据具体情况提出建议。本综述的目的是评估常见血液系统恶性肿瘤青少年和年轻人治疗的性腺毒性,并提供一个循证框架,以帮助在诊断、复发或耐药疾病以及长期随访时进行生育讨论和管理。